期刊文献+

比索洛尔治疗充血性心力衰竭合并快速房颤的疗效观察

Effects of Bisoprolol on patients with congestive heart failure and rapid atria fibrillations
下载PDF
导出
摘要 目的:观察比索洛尔治疗充血性心力衰竭(CHF)合并快速房颤(Af)的临床疗效。方法:将CHF并快速Af患者56例,随机分为治疗组、对照组各28例。对照组给予强心利尿等常规治疗,治疗组在常规治疗的基础上加用比索洛尔。疗程均为16周。结果:治疗组在临床疗效(92.86%)、心电图疗效(85.72%)以及心泵功能各项指标均明显优于对照组(P<0.01)。结论:比索洛尔治疗CHF并快速Af,既能有效控制心室率,又能显著改善心功能。 Objective:To evaluate the effects of Bisoprolol on patients with congestive heart failure (CHF) and rapid atria fibrillation (Af). Methods: Fifty - six patients with CHF and rapid Af were randomly divided into two groups. The patients of control group (28 cases) received routine treatment (diuretic, cardiac, glycoside, etc. ). The observation group (28 cases) was added with Bisoprolol. The whole course lasted for sixteen week. Results: After treatment, the clinical efficiencies and electrocardiogram efficien- cies in the observation group were 92.86% and 85.72%. It was clear better than routine treatment ( P 〈 0.01 ). Conclusions : Bisoprolol is effective and safe in the treatment of congestive heart failure and rapid atria fibrillation. It can both efficiently control heart rate and greatly improve cardiac function.
作者 徐绍勇
出处 《中国民康医学》 2007年第9期351-352,354,共3页 Medical Journal of Chinese People’s Health
关键词 比索洛尔 充血性心力衰竭 快速房颤 Bisonrolol Congestive heart failure: Ranid atria fibrillation
  • 相关文献

参考文献4

二级参考文献14

  • 1Anonymous. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure ( MERIT - HF). Lancet, 1999, 353 (9169): 2001.
  • 2Baran D, Horn EM, Hryniewicz K, et al. Effects of beta - blockers on neurohormonal activation in patients with congestive heart failure. Drugs, 2000,60(5): 997.
  • 3Ruffolo RR Jr, Feuerstein GZ, Ohlstein EH. Recent observations with beta - adrenoceptor blockade. Am J Hypertens, 1998,11 ( 1Pt 2): 9S.
  • 4Suwa M, Ito T, Otake Y, et al. Comparison of the therapeutic effects of the beta- blocking agent bisoprolol and the calciumblocking agent diltiazem in patients with heart failure due to dilated cardiomyopathy. Jpn Circ J,1996, 60(10): 767.
  • 5Domanski MJ, BEST Investigators. Beta - blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol, 2000,35(Suppl A):202.
  • 6Breithaupt - Grogler K, Ungethum W, Meurer - Witt B, et al.Pharmacokinetic and dynamic interactions of the angiotensin - converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. Eur J Clin Pharmacol, 2001,57(4): 275.
  • 7Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev, 2001,19(2): 152.
  • 8Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double- blind randomized study. J Am Coll Cardiol, 1995, 25(6): 1225.
  • 9Krum H, Sackner - Bernstein JD, Goldsmith RL,et al. Double -blind, placebo - controlled study of the long - term efficacy of carvedilol in patients with severe chronic heart failure. Circulation, 1995, 92(6): 1499.
  • 10Yoshikawa T, Handa S, Akaishi M, et al. Effect of a new beta -blocker, nipradilol, on cardiac function and neurohumoral factors in idiopathic dilated cardiomyopathy. Jpn Circ J 1996, 60 (5):285.

共引文献137

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部